Breadcrumb

[A11-31] Tafamidis - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission: Commission awarded on 2011-12-14 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 229 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form

Report documents

Report documents

PublishedDocumentSizeType 
2012-03-15 Extract of dossier assessment 229 kBPDFdownload file
2012-03-15 Dossier assessment (German version) 524 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Tafamidis - Benefit assessment according to § 35a Social Code Book V (dossier assessment) [PDF, 229 kB]

Federal Joint Committee (G-BA)

2012-06-07 A G-BA decision was published.

G-BA documents on this decision (German only)

Press releases

2012-03-15 Tafamidis: approval denotes proven added benefit



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close